Quick Answer
Bicara Therapeutics Inc. reported Research And Development Expense of $63.60 million for the year ending 2024.
- Bicara Therapeutics Inc. showed an increase of +107.8% in Research And Development Expense from 2023 to 2024.
- This data is from Bicara Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2025.
- XBRL data for this metric is available from 2023 to 2024 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Historical annual values: Fiscal year 2024: $63.60 million | Fiscal year 2023: $30.60 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: